Bath Cancer Research - Towards personalised medicine for every cancer patient

 


 


 

 

 

 

  

Bath Cancer Research is now closed.

For further information, contact agb<at>scientist<dot>com

Scientists at Bath Cancer Research undertook ex vivo drug sensitivity studies using the TRAC assay (Tumour Response to Anti-neoplastic Compounds, a development of the DiSC assay. With this we assessed the cytotoxic drug sensitivity of fresh human cells from patients with leukaemia and lymphoma. Our greatest expertise was with chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML or ANLL), non-Hodgkin's lymphoma (NHL) and similar diseases.

Here are selected publications from the work:

Selected Publications

Individualised Tumour Response Testing (ITRT) pages click here

  1. Bosanquet AG. Correlations between therapeutic response of leukaemias and an in-vitro drug-sensitivity assay. Lancet 1991; 337: 711-714.
    Abstract . PDF file of whole article
  2. Hinkley HJ, Bosanquet AG. The in vitro radiosensitivity of lymphocytes from chronic lymphocytic leukaemia using the differential staining cytotoxicity (DiSC) assay.I--Investigation of the method. International Journal of Radiation Biology 1992; 61: 103-110.
    Abstract. PDF file of whole article
  3. Hinkley HJ, Bosanquet AG. The in vitro radiosensitivity of lymphocytes from chronic lymphocytic leukaemia using the differential staining cytotoxicity (DiSC) assay. II--Results on 40 patients. International Journal of Radiation Biology 1992; 61: 111-121.
    Abstract. PDF file of whole article
  4. Bosanquet AG. The DiSC assay 10 years and 2000 tests further on. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP (Eds) "Drug resistance in leukemia and lymphoma. The clinical value of laboratory studies". London: Harwood 1993; 373-384.
  5. Bosanquet AG, Bell PB. Handling requirements to achieve active drugs in in_vitro drug sensitivity and resistance assays. In: Kaspers GJL, Pieters R, Twentyman PR,Weisenthal LM, Veerman AJP (Eds) "Drug resistance in leukemia and lymphoma. The clinical value of laboratory studies." London: Harwood 1993; 227-255.
  6. Bosanquet AG. In vitro drug sensitivity testing for the individual patient - an ideal adjunct to current methods of treatment choice. Clinical Oncology 1993; 5: 195-197. (Editorial)
  7. Fruehauf JP, Bosanquet AG. In vitro determination of drug response: A discussion of clinical applications. In: Cancer, Principals and Practice of Oncology, PPO updates.Eds. DeVita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott 1993; 7(12): 1-16. (Review)
    PDF file of whole article
  8. Bosanquet AG. Short-term in vitro drug sensitivity tests for cancer chemotherapy. A summary of correlations of test result with both patient response and survival. Forum Trends Experimental and Clinical Medicine 1994; 4: 179-195. (Review)
    Abstract. PDF file of whole article
  9. Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D. Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematologica 1995; 93: 73-79.
    Abstract. PDF file of whole article
  10. Bosanquet AG, Bell PB. Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology. Leukemia Research 1996; 20: 143-153.
    Abstract. PDF file of whole article
  11. Bosanquet AG, Bell PB. Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in CLL. Blood 1996; 87: 1962-1971.
    Abstract
  12. Bosanquet AG. Ex vivo Phase II trials and cross resistance with lithium gamma-linolenic acid. Annals of Oncology 1996; 7 (Suppl 1): 33. (Abstract)
  13. Bosanquet AG, Bell PB, Burlton AR, Amos TAS. Correlation of bcl-2 with P-glycoprotein expression in chronic lymphocytic leukaemia and other haematological neoplasms but of neither marker with ex_vivo chemosensitivity or patient survival. Leukemia and Lymphoma 1996; 24: 141-147.
    Abstract
  14. Bosanquet AG, Burlton AR, Bell PB, Harris AL. Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP. British Journal of Cancer 1997; 76: 511-518.
    Abstract . PDF file of whole article
  15. Bosanquet AG. Fludarabine: phosphate or no phosphate, that is the confusion. Clinical Cancer Research 1999; 5: 475-476 (letter).
    PDF file of letter
  16. Bell PB, Rooney N, Bosanquet AG. CD79a detected by ZL7.4 separating chronic lymphocytic leukemia from mantle cell lymphoma in leukemic phase. Communications in Clinical Cytometry 1999; 38: 102-105
    17. Abstract
  17. Mason JM, Drummond MF, Bosanquet AG, Sheldon TA. The DiSC assay: a cost-effective guide to treatment for chronic lymphocytic leukaemia? International Journal of Technology and Assessment in Health Care 1999; 15: 173-184.
    Abstract. PDF file of whole article
  18. Bosanquet AG, Johnson SA, Richards SM. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. British Journal of Haematology. 1999; 106: 71-77.
    Abstract. PDF file of whole article
  19. Bosanquet AG, Copplestone JA, Johnson SAN, Smith AG, Povey SJ, Gillingham R, Oscier DG. Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay. British Journal of Haematology 1999; 106: 474-476.
    Abstract. PDF file of whole article
  20. Bosanquet AG, Bell PB, Rooney N. Effect of interleukin-2 on CD95 (Fas/APO-1) expression in fresh chronic lymphocytic leukaemia and mantle cell lymphoma cells: relationship to ex vivo chemoresponse. Anticancer Res 1999; 19: 5329-5334.
    Abstract
  21. Bosanquet AG, Bosanquet MI. Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia. Leukemia 2000; 14: 712-715.
    Abstract. PDF file of whole article
  22. Bosanquet AG, Burlton AR, Bell PB. Parameters affecting the ex vivo cytotoxic drug sensitivity of normal human cells. J Exp Ther Oncol 2002; 2: 53-63.
    Abstract. PDF file of whole article
  23. Bosanquet AG, Sturm I, Wieder T, Essmann F, Bosanquet MI, Head DJ, Dörken B, Daniel P. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia 2002: 16: 1035-1044.
    Abstract. PDF file of whole article
  24. Sturm I, Bosanquet AG, Hermann S, Güner D, Dörken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003. 10: 477-484.
    Abstract. PDF file of whole article
  25. Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE, Joshi R, Mackie PH, Douglas IDC, Bowcock SJ, Catovsky D. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003 Dec; 82: 759-65.
    Abstract. PDF file of whole article
  26. Bosanquet AG, Bell PB. Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumour cells. J Exp Ther Oncol 2004; 4: 145-154.
    Abstract. PDF file of whole article
  27. Sturm I, Bosanquet AG, Hummel M, Dörken B, Daniel PT. In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer 2005; 5: 105.
    Abstract. PDF file of whole article
  28. Sturm I, Bosanquet AG, Radetzki S, Hummel M, Dörken B, Daniel PT. Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation. Int. J. Cancer 2006; 118: 2329–2336.
    Abstract. PDF file of whole article
  29. Bosanquet AG. Laboratory tests of cytotoxic drug sensitivity. Biomedical Scientist 2007; 51: 432-435.
    PDF file of whole article
  30. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJS, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P, on behalf of the UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group and NCRI Chronic Lymphocytic Leukaemia Working Group.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomised controlled trial.  Lancet 2007; 370: 230-239.
    Abstract.
  31. Bosanquet AG, Nygren P, Weisenthal LM.  Individualized Tumor Response Testing in Leukemia and Lymphoma. In: Kaspers GJ, Coiffier B, Heinrich MC, Estey EH, eds. Innovative leukemia and lymphoma therapy. New York: Informa Healthcare, 2008: 23-43. Buy the book Chapter
  32.  Bosanquet AG, Richards SM, Wade R, Else M, Matutes E, Dyer MJS, Rassam SMB, Durant J, Scadding SM, Raper SL, Dearden CE, Catovsky D.  Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing.  Br J Haem 2009; In press.

Recent abstracts and posters

1.              Else M, Bosanquet AG, Smith AG, Raper SL, Cocks K, Crofts S, Catovsky D.  An association between drug sensitivity by TRAC (DiSC) assay and quality of life in the UK LRF CLL4 trial.  Leukemia and Lymphoma 2007: 48 (Suppl 1); S148-S149 (Abstract P4.01).  Abstract

2.              Bosanquet AG, Durant J, Scadding SM, Raper SL, Else M, Catovsky D.  Nomograms of probability of response to chlorambucil, fludarabine or fludarabine plus cyclophosphamide based on TRAC ex vivo drug sensitivity results from the UK LRF CLL4 trial.  Leukemia and Lymphoma  2007: 48 (Suppl 1); S80-S81 (Abstract P1.53).  Abstract

3.              Bosanquet AG, Kaspers GJ, Larsson R, Nagourney RA, Nygren P, Pieters, R, Staib P, Tidefelt U, Zwaan CM, Weisenthal LM.  Individualized tumor response (ITR) profiling for drug selection in tailored therapy: meta-analysis of 1929 cases of leukemia and lymphoma.  Blood 2007: 110; 1017A (Abstract #3471).  Published abstract (with typos), Corrected abstract

4.              Bosanquet AG, Weisenthal LM, Nygren P, Tidefelt U, Larsson R, Zwaan CM, Kaspers GJ.  Personalised medicine: Individualised Tumour Response testing (ITRT) for leukaemia and lymphoma.  British Journal of Haematology 2008: 141 (Suppl 1); 25 (Abstract #68). Abstract

5.               Bosanquet AG, Durant J, Scadding SM, Rudin CE.  Activity of rapamycin against fresh human tumour and normal cells ex vivo.  In: National Cancer Research Institute (NCRI) Cancer Conference 2008; 5-8 Oct 2008; Birmingham, UK. NCRI; 2008 (Abstract B194).  Available at http://www.ncri.org.uk/ncriconference/2008abstracts/abstracts/B194.ht            

 

Date last modified: 6/4/09